Chao Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chao Wu has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Kefei Dou
Cardiometabolic Medicine Center, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
3 shared publications Chenxi Song
Cardiometabolic Medicine Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; State Key Laboratory of Cardiovascular Disease, Beijing, China; National Clinical Research Center for Cardiovascular Diseases, Beijing, China
2 shared publicationsRui Zhang
Department of Cardiology, Fuwai Hospital, National Clinical Research Center for Cardiovascular Diseases, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
2 shared publicationsXiaohui Bian
Cardiometabolic Medicine Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; State Key Laboratory of Cardiovascular Disease, Beijing, China; National Clinical Research Center for Cardiovascular Diseases, Beijing, China
2 shared publicationsZixiang Ye
Department of Cardiology, Fuwai Hospital, National Clinical Research Center for Cardiovascular Diseases, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
2 shared publications- Chen Zhu
College of Economics and Management, China Agricultural University
1 shared publication
Latest Publications
- Open Access
- 10 March 2026
- Published by Wolters Kluwer Health in Asian Heart Journal
- Vol. 2 (1) , 59-67
Aspirin-free strategy after short-term dual antiplatelet therapy in patients with complex percutaneous coronary intervention: A systematic review and network meta-analysis
Objectives: The transition from short dual antiplatelet therapy (DAPT) to P2Y 12 inhibitor monotherapy has recently gained popularity as a strategy to reduce aspirin-related bleeding while preserving the antithrombotic benefit of DAPT. However, the safety and efficacy of P2Y 12 inhibitor monotherapy after short-term DAPT in patients who received complex percutaneous coronary intervention (PCI) remains uncertain. Methods: The PubMed, EMBASE, Cochrane Library, and Web of Science were searched to identify randomized controlled trials published in any language between January 1980 and June 2023. Only peer-reviewed articles and randomized controlled trials were included. The primary efficacy and safety endpoints were major adverse cardiovascular events and major bleeding. We divided antiplatelet strategies into three categories based on previous clinical trials: P2Y 12 inhibitor monotherapy after 1 or 3 months DAPT, aspirin monotherapy after 3 or 6 months DAPT, and aspirin monotherapy after long-term (≥12 months) DAPT. The network meta-analysis was performed by the frequentist approach (PROSPERO-ID CRD42020192256). Results: Nine studies involving 16,201 patients with complex PCI were included. Within 1 year after complex PCI, the pooled results showed that compared with long-term DAPT, 1 or 3 months DAPT followed by P2Y 12 inhibitor monotherapy could significantly reduce the risk of primary efficacy endpoint (hazard ratio [HR], 0.67; 95% confidence interval [CI]: 0.52–0.87) as well as the risk of all-cause mortality (HR, 0.55; 95% CI, 0.37–0.81), target vessel revascularization (HR, 0.60; 95% CI, 0.45–0.79), and any bleeding events (HR, 0.52; 95% CI, 0.38–0.73). The indirect comparison revealed that P2Y 12 inhibitor monotherapy was correlated with a lower risk of major adverse cardiovascular events (HR, 0.44; 95% CI, 0.27–0.71), myocardial infarction (HR, 0.50; 95% CI, 0.28–0.90), and target vessel revascularization (HR, 0.61; 95% CI, 0.37–0.98) at 12 months compared with aspirin monotherapy after 3 or 6 months DAPT. Beyond 12 months, there were no significant differences in terms of major adverse cardiovascular events among these three antiplatelet treatments, while major bleeding (HR, 0.37; 95% CI, 0.14–0.94) resulted significantly lower, adopting an aspirin monotherapy strategy compared with prolonged DAPT. Conclusion: For patients with complex PCI, early discontinuation of DAPT to P2Y 12 inhibitor monotherapy might be a safer and equally effective strategy compared with aspirin monotherapy after 3 or 6 months or long-term DAPT.
- 10 March 2026
- Published by Wolters Kluwer Health in Asian Heart Journal
- Vol. 2 (1) , 59-67
Open AccessAspirin-free strategy after short-term dual antiplatelet therapy in patients with complex percutaneous coronary intervention: A systematic review and network meta-analysis
Objectives: The transition from short dual antiplatelet therapy (DAPT) to P2Y 12 inhibitor monotherapy has recently gained popularity as a strategy to reduce aspirin-related bleeding while preserving the antithrombotic benefit of DAPT. However, the safety and efficacy of P2Y 12 inhibitor monotherapy after short-term DAPT in patients who received complex percutaneous coronary intervention (PCI) remains uncertain. Methods: The PubMed, EMBASE, Cochrane Library, and Web of Science were searched to identify randomized controlled trials published in any language between January 1980 and June 2023. Only peer-reviewed articles and randomized controlled trials were included. The primary efficacy and safety endpoints were major adverse cardiovascular events and major bleeding. We divided antiplatelet strategies into three categories based on previous clinical trials: P2Y 12 inhibitor monotherapy after 1 or 3 months DAPT, aspirin monotherapy after 3 or 6 months DAPT, and aspirin monotherapy after long-term (≥12 months) DAPT. The network meta-analysis was performed by the frequentist approach (PROSPERO-ID CRD42020192256). Results: Nine studies involving 16,201 patients with complex PCI were included. Within 1 year after complex PCI, the pooled results showed that compared with long-term DAPT, 1 or 3 months DAPT followed by P2Y 12 inhibitor monotherapy could significantly reduce the risk of primary efficacy endpoint (hazard ratio [HR], 0.67; 95% confidence interval [CI]: 0.52–0.87) as well as the risk of all-cause mortality (HR, 0.55; 95% CI, 0.37–0.81), target vessel revascularization (HR, 0.60; 95% CI, 0.45–0.79), and any bleeding events (HR, 0.52; 95% CI, 0.38–0.73). The indirect comparison revealed that P2Y 12 inhibitor monotherapy was correlated with a lower risk of major adverse cardiovascular events (HR, 0.44; 95% CI, 0.27–0.71), myocardial infarction (HR, 0.50; 95% CI, 0.28–0.90), and target vessel revascularization (HR, 0.61; 95% CI, 0.37–0.98) at 12 months compared with aspirin monotherapy after 3 or 6 months DAPT. Beyond 12 months, there were no significant differences in terms of major adverse cardiovascular events among these three antiplatelet treatments, while major bleeding (HR, 0.37; 95% CI, 0.14–0.94) resulted significantly lower, adopting an aspirin monotherapy strategy compared with prolonged DAPT. Conclusion: For patients with complex PCI, early discontinuation of DAPT to P2Y 12 inhibitor monotherapy might be a safer and equally effective strategy compared with aspirin monotherapy after 3 or 6 months or long-term DAPT.
- Top Cited PapersOpen Access
- 2 March 2026
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 25 (1)
Prognostic stratification with composite insulin resistance–inflammation biomarkers in patients with chronic kidney disease and coronary artery disease across glycemic statuses
Patients with chronic kidney disease (CKD) and coronary artery diseases (CAD) have a poor long-term prognosis. Although insulin resistance (IR) and systemic inflammation are well-established drivers of cardiovascular risk, the prognostic value of their composite assessment across the glycemic spectrum in patients with CKD and CAD remains undetermined. This study aimed to evaluate the prognostic utility of composite IR-inflammation biomarkers for predicting mortality in patients with CKD and CAD stratified by glycemic status. 1353 patients with CKD and CAD were enrolled from National Health and Nutrition Examination Survey (NHANES) data (1999-2018). Composite biomarkers (TyG-hsCRP, TyG-CRP, and C-reactive Protein-Triglyceride Glucose Index [CTI]) were calculated. Patients were categorized by glycemic status (normoglycemia, prediabetes, diabetes) based on WHO/IEC criteria. The endpoint was all-cause and cardiovascular disease (CVD) death. Statistical analyses included Cox regression, Nelson-Aalen cumulative hazard plots with Log-rank test, restricted cubic splines, ROC curves, and reclassification metrics, adjusted for demographics, comorbidities, and treatments. Subgroup and sensitivity analyses ensured robustness. Over a median follow-up of 63-months, 744 all-cause and 323 CVD deaths occurred. Adjusted models showed elevated composite indices linked to higher mortality (e.g., CTI HR 1.43 [95% CI 1.24-1.65] for all-cause; HR 1.32 [1.06-1.64] for CVD). CTI provided good discrimination (AUC 0.700) and reclassification (IDI 0.010; NRI 0.196 for all-cause). The predictive utility of all three composite biomarkers was most pronounced in patients with diabetes, whereas CTI retained the strong association with all-cause mortality in normoglycemic and prediabetic patients. Risk stratification using both CTI and glycemic status identified patients with diabetes and high CTI as having the highest all-cause (HR 1.63 [1.22-2.17]) and CVD (HR 1.37 [0.88-2.14]) death risk. Composite biomarkers integrating IR and inflammation, particularly CTI, significantly enhance mortality prediction in patients with CKD and CAD. The predictive utility is modulated by underlying glycemic status, enabling refined risk stratification and potentially guiding tailored management strategies for this complex patient population.
- 2 March 2026
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 25 (1)
Top Cited PapersOpen AccessPrognostic stratification with composite insulin resistance–inflammation biomarkers in patients with chronic kidney disease and coronary artery disease across glycemic statuses
Patients with chronic kidney disease (CKD) and coronary artery diseases (CAD) have a poor long-term prognosis. Although insulin resistance (IR) and systemic inflammation are well-established drivers of cardiovascular risk, the prognostic value of their composite assessment across the glycemic spectrum in patients with CKD and CAD remains undetermined. This study aimed to evaluate the prognostic utility of composite IR-inflammation biomarkers for predicting mortality in patients with CKD and CAD stratified by glycemic status. 1353 patients with CKD and CAD were enrolled from National Health and Nutrition Examination Survey (NHANES) data (1999-2018). Composite biomarkers (TyG-hsCRP, TyG-CRP, and C-reactive Protein-Triglyceride Glucose Index [CTI]) were calculated. Patients were categorized by glycemic status (normoglycemia, prediabetes, diabetes) based on WHO/IEC criteria. The endpoint was all-cause and cardiovascular disease (CVD) death. Statistical analyses included Cox regression, Nelson-Aalen cumulative hazard plots with Log-rank test, restricted cubic splines, ROC curves, and reclassification metrics, adjusted for demographics, comorbidities, and treatments. Subgroup and sensitivity analyses ensured robustness. Over a median follow-up of 63-months, 744 all-cause and 323 CVD deaths occurred. Adjusted models showed elevated composite indices linked to higher mortality (e.g., CTI HR 1.43 [95% CI 1.24-1.65] for all-cause; HR 1.32 [1.06-1.64] for CVD). CTI provided good discrimination (AUC 0.700) and reclassification (IDI 0.010; NRI 0.196 for all-cause). The predictive utility of all three composite biomarkers was most pronounced in patients with diabetes, whereas CTI retained the strong association with all-cause mortality in normoglycemic and prediabetic patients. Risk stratification using both CTI and glycemic status identified patients with diabetes and high CTI as having the highest all-cause (HR 1.63 [1.22-2.17]) and CVD (HR 1.37 [0.88-2.14]) death risk. Composite biomarkers integrating IR and inflammation, particularly CTI, significantly enhance mortality prediction in patients with CKD and CAD. The predictive utility is modulated by underlying glycemic status, enabling refined risk stratification and potentially guiding tailored management strategies for this complex patient population.